BlueAllele is at the forefront of developing innovative gene correction technologies aimed at curing genetic diseases. The company focuses on its proprietary PALIDON® platform, which utilizes advanced repair template technologies to correct gene function in vivo. This platform is particularly significant as it leverages the non-homologous end joining (NHEJ) pathway, which is highly active in various cell types, including non-dividing cells. By employing a palindromic, bi-directional structure, PALIDON® templates are designed to achieve precise and durable gene corrections, addressing a wide range of monogenic diseases caused by single-gene mutations. This approach not only enhances the efficiency of gene correction but also minimizes unwanted byproducts, ensuring a safer application in therapeutic contexts.

In addition to its PALIDON® technology, BlueAllele is committed to advancing its research and development efforts to combine gene therapy and gene editing techniques. The company is actively working on the PALIDON+ platform, which aims to remove toxic mRNA and proteins while ensuring stable and lifelong expression of corrected genes. With a robust intellectual property portfolio that includes over 80 patent applications and several granted patents, BlueAllele is well-positioned to collaborate with partners in the gene editing therapeutics space. This strategic focus on transformative gene correction technologies underscores BlueAllele's mission to address some of the most challenging genetic diseases through innovative solutions.

United States

BlueAllele is working to address the unmet therapeutic challenges in gene editing. Our approach is based on the core principles of innovating and developing the next level of safe and effective treatments for patients with genetic disorders.

Our team excels at correcting genes at the DNA level, and has core strengths to move the field forward and develop new therapies.

BlueAllele

Company Details